DBV Technologies Skyrockets After European Regulator Accepts Peanut Allergy Patch Application

DBV Technologies (NASDAQ: DBVT) shares were trading higher Monday after the company announced that its Marketing Authorization Application for its investigational product Viaskin Peanut has been validated by the European Medicines Agency. 

DBV Technologies is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing and commercializing treatments for severe allergies in the United States and other global markets.

DBV's method of delivering biologically active compounds to the immune system is through self-administered and noninvasive products. The company also explores potential applications of its platform in vaccines and other immune diseases.

DBV Technologies shares were trading up 64.34% to $2.35 at last check Monday. The stock has a 52-week high of $13.49 and a 52-week low of $1.35.